New Two-Drug combo challenges standard care for tough esophageal cancer
NCT ID NCT07446335
Summary
This study is comparing a new two-drug combination (anlotinib + benmelstobart) against the current standard treatment (toripalimab + chemotherapy) for people with advanced esophageal cancer that has specific gene changes. It aims to see if the new combination is safer and more effective at controlling the cancer and helping patients live longer. The trial will enroll about 578 adults who have not yet received treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.